Free Trial

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

-0.01 (-0.10%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
50-Day Range
52-Week Range
1,900 shs
Average Volume
10,571 shs
Market Capitalization
$13.83 million
P/E Ratio
Dividend Yield
Price Target

Pieris Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Short Interest
1.12% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.93mentions of Pieris Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.34 out of 5 stars

Medical Sector

741st out of 922 stocks

Pharmaceutical Preparations Industry

348th out of 428 stocks

PIRS stock logo

About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

PIRS Stock Price History

PIRS Stock News Headlines

Pieris Pharmaceuticals: Q1 Earnings Snapshot
PIRS Apr 2024 2.500 call
Pieris Pharmaceuticals Inc (PIRS)
Pieris Pharmaceuticals, Inc. (PIRS)
Pieris Pharmaceuticals Inc PIRS
Pieris Pharma Cuts Around 70% Workforce; Plans Strategic Options
Pieris Pharmaceuticals (NASDAQ: PIRS)
See More Headlines
Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$42.81 million
Book Value
$16.64 per share


Free Float
Market Cap
$13.83 million
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Stephen S. Yoder J.D. (Age 48)
    CEO, President & Director
    Comp: $744.13k
  • Mr. Thomas Bures (Age 49)
    Senior VP, CFO & Treasurer
    Comp: $487.5k
  • Dr. Shane Olwill Ph.D. (Age 48)
    Senior VP & Chief Development Officer
    Comp: $463.91k
  • Maria Kelman
    Executive Director of Investor Relations
  • Mr. Prompong Chaikul (Age 37)
    Chief Supply Chain Officer
  • Dr. Florian Witte Ph.D.
    VP and Head of Alliance Management & Early Project Leadership

PIRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pieris Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PIRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PIRS, but not buy additional shares or sell existing shares.
View PIRS analyst ratings
or view top-rated stocks.

How have PIRS shares performed in 2024?

Pieris Pharmaceuticals' stock was trading at $14.56 at the start of the year. Since then, PIRS shares have decreased by 28.0% and is now trading at $10.48.
View the best growth stocks for 2024 here

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our PIRS earnings forecast

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) announced its earnings results on Friday, March, 29th. The biotechnology company reported ($4.00) earnings per share (EPS) for the quarter. The biotechnology company earned $1.30 million during the quarter. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 57.57% and a negative net margin of 39.71%.

When did Pieris Pharmaceuticals' stock split?

Pieris Pharmaceuticals's stock reverse split on the morning of Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Pieris Pharmaceuticals own?
Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include CM Management LLC (46.48%) and Summit Trail Advisors LLC (0.14%). Insiders that own company stock include Christopher P Kiritsy, Shane Olwill and Tim Demuth.
View institutional ownership trends

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PIRS) was last updated on 5/27/2024 by Staff

From Our Partners